Clinical trials: Pulmonary TB, active
Tuberculosis (TB)
Respiratory Health and Wellbeing Post Pulmonary Tuberculosis
We know that in low-income countries where there is a lot of tuberculosis (TB) about 20%-50% of people treated for TB have long term problems with their lungs and general wellbeing.
- Trial name
- RESPOST (NCT07178860)
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Liverpool School of Tropical Medicine
Tuberculosis, Pulmonary
Post TB Sequelae Study
The goal of this prospective cohort study is to learn about the long-term health effects of tuberculosis (TB) in children, adolescents, and adults who have completed standard TB treatment in Bangladesh.
- Trial name
- NCT06744179
- Testing
- echocardiography, chest x-ray, full blood count , SGPT, lipid profile, HbA1C, AQ20 questionnaire, mmRC dyspnoea scale, Duke activity status index, COPD assessment test, Age and stage questionnaire
- Where
- Bangladesh
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Pulmonary Infection, Pulmonary Nodule
Remimazolam for Bronchoscopy in High-Risk Patients
Bronchoscopy is currently widely used for the diagnosis and treatment of various respiratory diseases. However, the operation of bronchoscopy is irritating, causes a strong stress response, and shares the airway with the patient…
- Conditions
- Pulmonary Infection, Pulmonary Nodule, Phthisis, Endotracheal Tumour
- Trial name
- NCT07395596
- Testing
- propofol and alfentanil, remimazolam combined with propofol and alfentanil
- Where
- 2 sites in China
- Volunteers
- 360 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Tuberculosis, Pulmonary
Sorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TB
The goal of this interventional trial is to evaluate the safety and efficacy of the loading dose regimen 200/100SPaL-4/13 weeks, and the 100SPaL -17 weeks regimen in adults with newly diagnosed, drug-sensitive, smear-positive…
- Trial name
- NCT07672405
- Testing
- sorfequiline, Pretomanid, Linezolid
- Where
- 12 sites in South Africa, Tanzania
- Volunteers
- 100 people
- Sponsor
- Global Alliance for TB Drug Development
Tuberculosis, Pulmonary
Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB
This study is being done to test an experimental study vaccine compared to a placebo. The experimental study vaccine is called ID93 + GLA-SE.
- Trial name
- NCT06205589
- Testing
- ID93 + GLA-SE vaccine
- Volunteers
- 1,500 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Adjuvant, Treatment
Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis
This study is designed to further strengthen the clinical application evidence of BaidiZiyin Pill and ShenqiYifei Pill in the treatment of tuberculosis.
- Conditions
- Adjuvant, Treatment, Tuberculosis
- Trial name
- NCT06403943
- Testing
- BaiDiZiYin Pill, ShenQiYiFei Pill, Anti tuberculosis chemotherapy
- Where
- China
- Volunteers
- 292 people
- Sponsor
- Beijing Chest Hospital
Tuberculosis (TB)
A Confirmatory Trial of Adjunctive NAC to Prevent Post Tuberculosis Lung Disease
The goal of this clinical trial is to evaluate if N-acetylcysteine (NAC) works to prevent post-tuberculosis lung disease (PTLD) in patients with severe pulmonary impairment. It also aims to assess the safety of NAC.
- Trial name
- NAC-PTLD (NCT06909799)
- Testing
- N-Acetyl Cysteine (NAC), Standard TB treatment
- Where
- The Gambia
- Volunteers
- 242 people
- Sponsor
- The Aurum Institute NPC
Pulmonary Tuberculoses, Aspergillosis
Pulmonary Aspergillosis in Tuberculosis Patients
Pulmonary tuberculosis (PTB) is the most common cause of lung destruction, contributing to coinfections development, and Aspergillosis spp. is one of the most important.
- Conditions
- Pulmonary Tuberculoses, Aspergillosis, Old Tuberculosis, Active Tuberculosis
- Trial name
- NCT05045391
- Testing
- Aspergillus IgG detection
- Where
- Uzbekistan
- Volunteers
- 200 people
- Sponsor
- Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan
Tuberculosis, Acute Coronary Syndrome
Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis
Tuberculosis (TB) is a global pandemic that despite successful treatment and bacterial eradication can cause chronic ill health, such as pulmonary impairment after tuberculosis (PIAT) and cardiovascular disease (CVD).
- Conditions
- Tuberculosis, Acute Coronary Syndrome, Pulmonary Hypertension (Diagnosis)
- Trial name
- Doxy-TB (NCT05473520)
- Testing
- Doxycycline
- Where
- 6 sites in Malaysia, Singapore
- Volunteers
- 150 people
- Sponsor
- National University Hospital, Singapore
Covid-19 Pandemics, Tuberculosis
Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients
This study is a non-randomized observation and comparison of immune response between bacteriologically confirmed TB patients under treatment cohort who received COVID-19 vaccine (n=54) vs healthy individuals (n=54).
- Trial name
- CVTB (NCT05571735)
- Testing
- Pfizer-BioNTech COVID-19 vaccine, AstraZeneca vaccine, Janssen Ad26.COV2.S COVID-19 vaccine
- Where
- Thailand
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis, Inflammation Biomarkers
Effects of Adjunct Omega-3 Long Chain Polyunsaturated Fatty Acids in Pulmonary Tuberculosis Patient: an Early Bactericidal Activity and Inflammatory Trial
The goal of this randomized controlled trial is to evaluate the early bactericidal activity, early inflammatory response, and safety of omega-3 long chain polyunsaturated fatty acid (n-3 PUFA) supplementation in adult patients…
- Conditions
- Tuberculosis, Inflammation Biomarkers, Liver Function Tests, Iron Status
- Trial name
- TREAT 3 (NCT07118059)
- Testing
- Omega-3 (EPA+DHA)
- Where
- South Africa
- Volunteers
- 40 people
- Sponsor
- North-West University, South Africa
Pulmonary Tuberculosis, Treatment Adherence
Effectiveness of Psychosocial Counseling in Patients With a New Tuberculosis Diagnosis
Introduction: Newly diagnosed TB patients frequently experience psychological distress, stigma, and concerns regarding treatment duration, side effects, and social consequences, which may negatively affect adherence.
- Conditions
- Pulmonary Tuberculosis, Treatment Adherence, Mental Health
- Trial name
- NCT07703696
- Testing
- psychosocial counseling
- Where
- Indonesia
- Volunteers
- 108 people
- Sponsor
- Universitas Diponegoro
Tuberculosis, Pulmonary
Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting
This study will look at whether press-needle ear acupuncture can help lower nausea and vomiting caused by antituberculosis medicines in people with pulmonary tuberculosis.
- Trial name
- NCT07271225
- Testing
- Press Needle
- Where
- Indonesia
- Volunteers
- 58 people
- Sponsor
- Universitas Indonesia
Pulmonary Tuberculosis
A PAN-USR TB Multi-Center Trial
Tuberculosis (TB) remains a major public health issue and one of the top ten causes of death from a single infectious disease worldwide.
- Trial name
- NCT06905522
- Testing
- Bedaquiline (B), Sitafloxacin (S), Linezolid (L)
- Where
- 3 sites in China
- Volunteers
- 610 people
- Sponsor
- Shenzhen Third People's Hospital
Tuberculosis, Pulmonary
A Short Regimen for Rifampicin-resistant Isoniazid-susceptible TB
To assess outcome of treatment and safety among patients with rifampicin-resistant isoniazid-susceptible pulmonary tuberculosis treated with a novel regimen consisting of isoniazid, bedaquiline, and moxifloxacin throughout for 6…
- Trial name
- NCT06526039
- Testing
- a novel short regimen
- Volunteers
- 100 people
- Sponsor
- Taipei Medical University WanFang Hospital
Tuberculosis in HIV-infected Individuals, Drug Susceptible Pulmonary Tuberculosis
Short-Course Regimens for DS-PTB in AIDS Patients
This study adopts a multicenter, open-label, randomized controlled design, conducted across key designated AIDS diagnosis and treatment hospitals nationwide.
- Trial name
- NCT07608172
- Testing
- 2HPMZ/2HPM, 2HRZE/4HR
- Volunteers
- 148 people
- Sponsor
- Shanghai Public Health Clinical Center
Drug Susceptible Pulmonary Tuberculosis
Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis
The purpose of this study is to evaluate if TBD09 in combination with other active agents in adults with drug sensitive pulmonary tuberculosis has potential to be safe and effective.
- Trial name
- NCT07525427
- Testing
- Bedaquiline, pretomanid and TBD09, Bedaquiline, pretomanid and linezolid
- Where
- 13 sites in South Africa
- Volunteers
- 150 people
- Sponsor
- Gates Medical Research Institute
Tuberculosis, Tuberculosis, Pulmonary
Shortened Regimen for Drug-susceptible TB in Children
While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs.
- Conditions
- Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node, Mycobacterium Tuberculosis
- Trial name
- SMILE-TB (NCT06253715)
- Testing
- Isoniazid, Rifampin, Pyrazinamide
- Where
- 9 sites in India, Indonesia and 5 more
- Volunteers
- 860 people
- Sponsor
- Johns Hopkins University
TB - Tuberculosis, HIV/AIDS
Pre- and Post-treatment Lung Microbiota, Metabolome and Immune Signatures at the Site of Disease in Patients With Active Pulmonary Tuberculosis
The diverse microbial communities in different parts of the human body (microbiome) are important for health but understudied in pulmonary tuberculosis (TB), which is the single biggest infectious cause of death in the world.
- Trial name
- TB-LUNG (NCT04700579)
- Where
- 3 sites in South Africa
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Stellenbosch
TB - Tuberculosis, PTLD
Intergrated Service Delivery for Lung Health Conditions
The Advancing Lung Health in Zambia project aims to improve access to integrated screening, diagnosis, and management of tuberculosis (TB) and other priority respiratory diseases at community and primary healthcare levels.
- Conditions
- TB - Tuberculosis, PTLD, COPD (Chronic Obstructive Pulmonary Disease), Computer Aided Diagnosis
- Trial name
- TB REACH W11 (NCT07816523)
- Testing
- Intergrated lung health screening, AI-Enabled Cough Sound Screening for Tuberculosis, Post-TB Lung Disease evaluation
- Where
- Zambia
- Volunteers
- 20,300 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia